Forget the Clinical Museum: Repositioning Event Strategy for Commercial Velocity
Clinical superiority is the baseline, not the differentiator. Life sciences CMOs who are still allocating the majority of their event budget to broadcasting trial data are competing for a distinction that payers and procurement heads stopped rewarding some time ago. What do life sciences buyers actually evaluate at trade shows? The investment in scientific infrastructure signals where the industry is heading. Thermo Fisher's $75 million Cryo-EM Drug Discovery Center in South San Francisco is a statement about scientific ambition at near-atomic resolution. The commercial question is whether the marketing infrastructure surrounding that science can communicate its implications to the buyers standing on the congress floor — payers, providers, and procurement leaders who are asking a different question entirely: how fast can we…